ALK rearrangement occurs in approximately 3%–5% of non-small cell lung cancer (NSCLC)
[
[1]
]. Ensartinib is a potent new-generation ALK inhibitor with high activity and is well-tolerated
in patients with crizotinib-resistant, ALK-positive NSCLC, including those with CNS
metastases [
- Wu K.L.
- Chen H.L.
- Tsai Y.M.
- et al.
First-line anaplastic lymphoma kinase (ALK) inhibitors for ALK-positive lung cancer
in asian populations: systematic review and network meta-analysis.
J Clin Med. Sep 25 2021; 10https://doi.org/10.3390/jcm10194376
[2]
]. Ensartinib represents a new first-line option for patients with ALK-positive NSCLC.
And ensartinib had an acceptable safety profile: low proportions of patients required
dose modifications or discontinued the study and most treatment-related adverse events
were grade 1 or 22. Evidence of the effectiveness of ensartinib as neoadjuvant therapy in locally advanced
NSCLC with ALK rearrangement is limited. At present, there are no case reports of
ensartinib as neoadjuvant treatment. Here, we report a case of locally advanced adenocarcinoma
harbouring ALK rearrangements with a pathological complete tumour response after ensartinib
treatment.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- First-line anaplastic lymphoma kinase (ALK) inhibitors for ALK-positive lung cancer in asian populations: systematic review and network meta-analysis.J Clin Med. Sep 25 2021; 10https://doi.org/10.3390/jcm10194376
- Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.Lancet Respir Med. Jan 2020; 8: 45-53https://doi.org/10.1016/s2213-2600(19)30252-8
- Ensartinib (X-396) in ALK-positive non-small cell lung cancer: results from a first-in-human phase I/II, multicenter study.Clin Cancer Res : Off J Am Assoc Cancer Res. Jun 15 2018; 24: 2771-2779https://doi.org/10.1158/1078-0432.ccr-17-2398
- The emerging therapeutic landscape of ALK inhibitors in non-small cell lung cancer.Pharmaceuticals. Dec 18 2020; 13https://doi.org/10.3390/ph13120474
- Feasibility and safety of neoadjuvant alectinib in pulmonary invasive mucinous adenocarcinoma with ALK rearrangement: case report and literature review.OncoTargets Ther. 2021; 14: 5107-5113https://doi.org/10.2147/ott.s334213
Article info
Publication history
Published online: May 11, 2022
Accepted:
April 4,
2022
Received:
March 27,
2022
Identification
Copyright
© 2022 Elsevier Ltd. All rights reserved.
